OGD2 Pharma and Syndivia launch collaboration to develop an Antibody-Drug Conjugate (ADC) targeting the O-acetyl-GD2 cancer antigen

A few months after announcing its collaboration with the Korean pharmaceutical company GreenCross in cell therapy, OGD2 Pharma is getting into ADC (Antibody Drug Conjugates, antibody conjugated anti-cancer) with Syndivia, a French company specialized in this segment. Press release (EN) : OGD2 Pharma SAS, a biotechnology company developing innovative anti-cancer… read more →